Primary outcome:~To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC~Secondary outcome:~pathologic complete response (pCR)、Major Pathologic Response（MPR）、R0 resection rate、Objective response rate（ORR）、Disease free survival（DFS）、Relief rate and safety of dysphagia
To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC